NasdaqCM - Delayed Quote USD

Telomir Pharmaceuticals, Inc. (TELO)

1.9600

-0.0400

(-2.00%)

At close: June 13 at 4:00:01 PM EDT

2.0000

+0.04

+(2.04%)

After hours: June 13 at 5:21:52 PM EDT

TELO Rises on Promising Telomir-1 Preclinical Results

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is among the 10 Best Growth Stocks Under $100 to Buy Now. On Wednesday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) revealed that its leading product, Telomir-1, showcased a marked improvement in the neurological, liver, and kidney symptoms observed in a preclinical animal model of Wilson’s disease. In a zebrafish model mimicking Wilson’s disease, […]

Insider Monkey yesterday

TELO
-2.00%
Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model

Treatment reversed tremors, ataxia, anxiety-like behavior, liver and kidney pathology damage, reduced copper accumulation, normalized ALT, AST, and bilirubin levels, and improved survival. Building on previous data in Werner syndrome, showing Telomir-1 ...

ACCESS Newswire 3 days ago

TELO
-2.00%
TELO Continues Trend of Significant Trial Announcements

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to reverse biological aging and degenerative diseases. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing

Zacks Small Cap Research 3 days ago

TELO
-2.00%
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome

Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival - highlighting Telomir-1's potential to reverse key hallmarks of aging MIAMI, ...

ACCESS Newswire 9 days ago

TELO
-2.00%
EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder

Telomir Pharmaceuticals Inc. (NASDAQ:TELO) on Thursday released new preclinical data for its lead candidate, Telomir-1. The data demonstrated that Telomir-1, administered orally, significantly increases telomere length, reverses body weight and muscle loss, and resets cellular aging markers in a validated animal model of Werner Syndrome (WS)—a rare genetic disorder also known as adult-onset progeria. Adult progeria is a rare genetic disorder characterized by premature aging starting in late adol

Benzinga 9 days ago

TELO
-2.00%
TELO Data Indicates Aging Reversal Potential

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing

Zacks Small Cap Research 10 days ago

TELO
-2.00%
Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform

Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human dosing in the first half of 2026 MIAMI, FL / ACCESS Newswire / June 2, 2025 / Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) ("Telomir" ...

ACCESS Newswire 12 days ago

TELO
-2.00%
Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints

A unique oral drug candidate that is shown to restore vision and regenerate the retina in an animal model, addressing a major unmet need in ocular therapeutics MIAMI, FLORIDA / ACCESS Newswire / May 29, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ...

ACCESS Newswire 16 days ago

TELO
-2.00%
TELO Produces Results with Exciting AMD Implications

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing

Zacks Small Cap Research 17 days ago

TELO
-2.00%
Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND

Investment from largest shareholder strengthens balance sheet, signals insider conviction, and funds Telomir-1's upcoming IND submission for a rare disease indication MIAMI, FLORIDA / ACCESS Newswire / May 21, 2025 / Telomir Pharmaceuticals, Inc. ...

ACCESS Newswire 24 days ago

TELO
-2.00%
EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND

On Wednesday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced that it had secured $3 million in equity financing through a direct investment by The Bayshore Trust, the company's largest shareholder. The transaction involved the purchase of 1 million restricted shares of the company's common stock at $3.00 per share, representing an 18% premium to Telomir's closing share price of $2.54 on the execution date. The transaction was structured as a straight restricted common stock transaction. A

Benzinga 24 days ago

TELO
-2.00%
Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity

Antimicrobial resistance is recognized as one of the top global public health threats, and Telomir-Ag2 strengthens Telomir's pipeline with a differentiated candidate designed to address this urgent and expanding crisis MIAMI, FL / ACCESS Newswire ...

ACCESS Newswire 30 days ago

TELO
-2.00%
TELO Announces Exciting Discovery

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing

Zacks Small Cap Research 30 days ago

TELO
-2.00%
Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia

MIAMI, FLORIDA / ACCESS Newswire / May 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), a leader in age-reversal science, today announced new preclinical data showing that its lead oral drug candidate, Telomir-1, reverses multiple ...

ACCESS Newswire last month

TELO
-2.00%
TELO Announces Promising Aging Reversal Test Results

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing

Zacks Small Cap Research last month

TELO
-2.00%
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells

Telomir-1 Inhibits Tumor Growth, Suppresses Cancer Progression, and Neutralizes Chemotherapy Toxicity MIAMI, FLORIDA / ACCESS Newswire / March 19, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), a leader in age-reversal science, today ...

ACCESS Newswire 2 months ago

TELO
-2.00%
TELO Study Shows Cancer-Related Breakthrough

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing

Zacks Small Cap Research 2 months ago

TELO
-2.00%
Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines

New Study Confirms Telomir-1 Also Reverses Oxidative Stress, Preserves Cellular Integrity, and Prevents Cell Death by Protecting Mitochondria-The Cell's Power Source and Gatekeeper of Life and Death MIAMI, FLORIDA / ACCESS Newswire / February 26, ...

ACCESS Newswire 3 months ago

TELO
-2.00%
3 US Penny Stocks To Consider In February 2025

As of February 2025, U.S. markets have been experiencing a mixed performance, with the S&P 500 and Nasdaq falling for the fourth consecutive day amid concerns about economic outlook and policy impacts. Despite these challenges, investors often look to penny stocks as a potential area for growth due to their affordability and the unique opportunities they present. While once considered speculative, penny stocks can still offer compelling prospects when backed by strong financials, making them...

Simply Wall St. 3 months ago

CCG

CCGWW

PMVP
Telomir Pharmaceuticals Says Telomir-1 Compound Stabilizes Silver for Advanced Medical Applications

Telomir Pharmaceuticals (TELO) said Friday it was able to stabilize both Silver(I) and the highly re

PREMIUM
MT Newswires 3 months ago

TELO
-2.00%

Performance Overview

Return	TELO	S&P 500 (^GSPC)
YTD	-52.43%	+1.62%
1-Year	-65.19%	+10.00%
3-Year	-72.00%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Telomir Pharmaceuticals, Inc. (TELO)

TELO Rises on Promising Telomir-1 Preclinical Results

Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model

TELO Continues Trend of Significant Trial Announcements

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome

EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder

TELO Data Indicates Aging Reversal Potential

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints

TELO Produces Results with Exciting AMD Implications

Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND

EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND

Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity

TELO Announces Exciting Discovery

Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia

TELO Announces Promising Aging Reversal Test Results

Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells

TELO Study Shows Cancer-Related Breakthrough

Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines

3 US Penny Stocks To Consider In February 2025

Telomir Pharmaceuticals Says Telomir-1 Compound Stabilizes Silver for Advanced Medical Applications

Performance Overview